Novel Delivery Strategies for Oligos and Peptides - $600 Savings End Friday, 1/29

Register by this Friday, January 29th and receive up to a $600 savings – Use the code B16180BLOG100 to save. Click here to register.

Recent advances in delivery strategies have paved the way for improved targeting, efficacy and patient usability for the oligonucleotide and peptide therapeutic industry. Ensure that your team is up-to-date on the latest drug delivery strategies for accelerated product development by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

Register today to attend the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization.

Industry Experts Present Novel Delivery Strategies for Oligonucleotides and Peptides:


Centyrins as Targeting Agents for Next-Generation Modular Therapeutics
Vadim Dudkin, Ph.D., Scientific Director, Centyrex, Johnson & Johnson

The biophysical properties of Centyrins make them ideal as targeting agents for a variety of novel delivery technologies. Centyrex is exploiting this platform via novel therapeutic applications aimed at addressing outstanding challenges in...(continue reading)
________________________________________

Treatment Opportunities for Cystic Fibrosis Using Aerosolized Antisense Oligonucleotides
Shuling Guo, Ph.D., Director, Antisense Drug Discovery, Isis Pharmaceuticals

Cystic fibrosis (CF) is one of the most common life-threatening genetic diseases affecting ~30,000 people within US and ~70,000 worldwide. Lung disease is the major cause of morbidity and mortality in CF. Antisense oligonucleotides (ASOs) administered by aerosol delivery distribute broadly into...(continue reading)
________________________________________

ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous Osmotic Mini-Pump) an Investigational Therapy for Type-II Diabetes
Scott Peterson, Ph.D., Executive Director, Corporate Development, Intarcia Therapeutics, Inc.

ITCA 650, an investigational therapy for T2DM currently in Phase 3 clinical trials, is an osmotic mini-pump that can subcutaneously deliver exenatide (a GLP-1 receptor agonist) for extended periods of time. This presentation will cover the technology behind...(continue reading)


For more session information, download the complete agenda.

Share this article with your social network, just click below to share now!

Share |

8 Reasons Why You Can't Miss BPI West | Plus! Register by Friday, 1/22 and Save $400

8 Reasons Why You Can't Afford to Miss BPI West:

1. First and only phase-based format event that fosters the collective sharing ideas, strategies and solutions across departments to improve speed, cost and quality at every stage of development
2. Breakdown the barriers and collaborate across stages of development to achieve end-to-end integration
3. Discover the latest breakthroughs on successfully implementing continuous processes and linking them together to achieve fully continuous processing from cell culture through to drug substance
4. Accelerate the design and development of novel drug substances for next generation therapeutics by integrating candidate selection and early development
5. Develop strategies for fast tracking early stage biologics and managing the life cycle of a break through therapy designated product
6. Speed up and streamline the transition into development by utilizing manufacturability assessments, automation, and QbD in late stage discovery and R&D
7. Implement disruptive technologies and achieve operational excellence to drive manufacturing efficiencies and minimize costs
8. Uncover the future of single-use systems and next generation facility design, modelling and management in current and emerging markets

Want to learn more about the event? Download the brochure.

Register by this Friday, January 22nd and receive up to $400 in savings - Use the code BPIWEST16BL to save.

Share this article with your social network, just click below to share now!

Share |

LAST CHANCE | Save $550 to Antibody Engineering & Therapeutics

As the largest and most trusted antibody engineering and therapeutics event in the industry, IBC's Antibody Engineering & Therapeutics continues to showcase an impressive collection of world-renowned and highly-published academic and industry scientists, as they share the latest science, strategies and preclinical/clinical development efforts.

Get a sneak peek at the high caliber sessions and happenings of the event by watching the 2014 event highlights:



By attending this event, you will learn from 120+ speakers and connect with over 700 of your peers to help you discover, engineer and develop novel and next-generation antibody modalities. In addition, you will gain fresh ideas and new perspectives to accelerate your current project by viewing over 100 academic and industry poster presentations covering the latest cutting edge antibody research.

To see full session & speaker details, download the brochure.

But you have to be registered first to get access! Register today to take advantage of the early-bird savings of up to $550. Be sure to use code D15172BLOG. The savings expire tomorrow, Friday, August 28th—so hurry! Register now.

Share this article with your social network, just click below to share now!

Share |

Biosimilars: Seven Cold Hard Facts

On July 24^th the FDA accepted its first application for a biosimilar drug in the U.S. and put the industry on alert that this new market is fast approaching.   While no one knows exactly when the first approval will come, here are a few facts to bring you up to speed for when it does: 

·      •  Estimates on savings attributed to biosimilars range from $42 - $108 billion over the first ten years of the market.

      •  The value of biologics slated to come off patent by 2017 is about $70 billion.

•  Per the Rheumatology Network, over the span of their lifetime, many drugs approved in the US and EU have eventually become “biosimilars” of themselves.  This is due to a “natural drift” in drug properties caused by changes in production such as using different batches of medium or manufacture at different sites.

        •  Recently, a group of 19 investors representing nearly $430 billion in assets  commended Novartis and Amgen for supporting a set of investor principles to guide boards on activities related to biosimilars. 

    •  A survey conducted among senior’s organization RetireSafe shows that 92% were unaware that the Affordable Care Act potentially allows for biosimilar drugs to be substituted for a biologic.  Furthermore, this could potentially be done without the patient or doctor being aware.

•  Hospira is looking to file its first biosimilar in the US within twelve months and currently has an R&D pipeline valued at around $40 billion.  

•  Amgen is developing a portfolio of biosimilars of which three are slated to launch in 2017.   

We’ll have more on the latest developments in the biosimilars market at the 15^th Annual Business of Biosimilars meeting. Join us October 20-22 in Boston, MA.  Download the agenda to see what’s on tap.

SAVE $100.  Register here and use code XP1986BLOG.

Follow us on Twitter: @FutureOfBiopharma & @Biosimilars
Join us on LinkedIn

Share this article with your social network, just click below to share now!

Share |